Novartis returns to appellate court, requesting rehearing and reversal in Gilenya patent case
Novartis may have suffered a setback in court over its blockbuster neuroscience drug Gilenya, but the pharma giant isn’t done fighting for it.
A month after the US Court of Appeals for the Federal Circuit ruled 2-1 against Novartis in a patent infringement case, the Swiss pharma giant filed a motion requesting to be heard either by a new panel or en banc, which means all judges of the court hear the case, instead of 1 or a panel of 3. By law, there are 12 judges on the court.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
